Following a recent capital increase Fund+ now has €125m to spend on drug developers, medtech firms and in vitro diagnostic research in Belgium – with a big dream of creating sustainable shareholder value and a leadership position for the Belgian life sciences sector, while also generating a beneficial societal impact.
The fund, which launched in 2015, has made six investments so far, most of which target the busy pipeline areas...






